SUDA’s treatment is a first-in-class oral spray formulation of sumatriptan (marketed in tablet form and in a nasal spray by GlaxoSmithKline under the brand name Imitrex®). Sumatriptan is one of the most widely used drugs for the treatment of acute migraine in adults and works by narrowing the blood vessels in the brain.
SUDA has entered into an exclusive product development, licence and supply agreement with Strides Pharma Global Pte Ltd, a fully-owned subsidiary of Strides Pharma Science Ltd, (“Strides”) for the development and commercialisation of SUDA’s novel fast acting oral spray of sumatriptan to treat migraine headache for the United States.
Migraine is a painful and debilitating condition that disrupts lives, impacts careers and costs employers in lost work and diminished productivity. According to a 2011 WHO report, migraine affects about 11% of the global adult population and the market value for the same year was estimated to be around US$3.2bn and is forecast to reach US$4.4bn by 2020.